• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Report: U.K. biotech pulling ahead in Europe

Report: U.K. biotech pulling ahead in Europe

July 27, 2015
CenterWatch Staff

Over the past 10 years, the U.K. biotech sector has outperformed other European countries, raising $1.4 billion via IPOs and $2.4 billion in venture capital, according to a new report from life science market intelligence firm Evaluate and the U.K. BioIndustry Association (BIA). The rise in optimism has been most evident in 2014, with the momentum continuing into 2015.

2014 was a big turning point for the U.K. biotech sector. In that year alone, nine companies listed on the public market raised a total of £408 million, almost half of the total IPO haul for the past decade.

U.K. venture capital financing also improved in 2014, jumping 71% from the previous year to $430 million, with VC firms doing fewer, bigger rounds at an earlier stage. On the flip side, seed funding of early-stage companies by venture capital has fallen dramatically and highlights the need for alternative funding and the return of specialist investors willing to take a more long-term view of the industry.

Report highlights included:

  • Strong confidence in the U.K. market is reflected in recent IPO activity reaching $634 million in 2014, with two additional IPOs in 2015.
  • Good stock market performance of new entrants, including 247% share gain by 4D Pharma since its IPO, helped to highlight the benefits of investing in the sector.
  • An increase in exits (via IPO and trade sales) -has created a 10-year record in venture funding: Investment in 2014 is up 71% to $430 million (2013: $251 million).
  • Fewer larger financing deals took place in 2014, indicating a change in investment style.
  • Venture capital seed funding declined dramatically to one deal in 2014; although the $20 million raised equaled almost the total of the last four years combined.
  • The U.K. is holding its own against the U.S. outperforming Europe in the past five years for venture funding.

Lisa Urquhart, report author and editor of EP Vantage, the editorial arm of Evaluate, said, “These recent gains have been hard-won. As we enter the second half of 2015, it will be interesting to see if any indicators of the future direction of the U.K. sector can be spotted. What is obvious is that if we are to maintain this momentum, we need to see a big jump in seed funding—crucial to grow and retain U.K. innovation.”

Steve Bates, CEO of the BIA, said, “It is clear that the U.K. biotech funding ecosystem has learned lessons from its history and is doing things differently this time around. We are seeing the development of different forms of investment for innovative U.K. companies. In contrast to the more generalist U.S. investors, the U.K.’s specialist investors understand the need for patience, restocking funds while capital is plentiful, giving well-backed U.K. companies more financial runway to succeed.”

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing